3.19
+0.0106(+0.33%)
Currency In USD
| Previous Close | 3.18 |
| Open | 3.21 |
| Day High | 3.25 |
| Day Low | 3.07 |
| 52-Week High | 4.98 |
| 52-Week Low | 1.05 |
| Volume | 48,026 |
| Average Volume | 157,355 |
| Market Cap | 29.19M |
| PE | -12.76 |
| EPS | -0.25 |
| Moving Average 50 Days | 2.64 |
| Moving Average 200 Days | 2.29 |
| Change | 0.01 |
If you invested $1000 in iBio, Inc. (IBIO) 10 years ago, it would be worth $1.12 as of February 05, 2025 at a share price of $3.191. Whereas If you bought $1000 worth of iBio, Inc. (IBIO) shares 5 years ago, it would be worth $18.23 as of February 05, 2025 at a share price of $3.191.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iBio Announces New Investments from Board Members and Officers
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with members of its Board of Directors and Officers, to
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
GlobeNewswire Inc.
Jan 07, 2025 12:00 PM GMT
Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug and target discovery platform potentialSAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
GlobeNewswire Inc.
Jan 02, 2025 12:00 PM GMT
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight Regain, Potentially Enabling Less Frequent Dosing tha